ALEXANDRIA, Va., July 3 -- United States Patent no. 12,344,651, issued on July 1, was assigned to Novartis AG (Basel, Switzerland).

"CD19 and CD22 chimeric antigen receptors and uses thereof" was invented by Boris Engels (Arlington, Mass.) and Carla Patricia Guimaraes (Boston).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors enco...